A group of researchers in India have looked into the role of estrogen-related receptor γ (ERRγ) in the progression of colorectal cancer (CRC), and studied the effect of combination therapy with an ERRγ inverse agonist, DN-200434, and the AKT inhibitor MK-2206 in in vitro and in vivo assays.